Worldwide: Navigating Patent Minefields In Emerging Asian Medtech Markets

Last Updated: February 2 2016
Article by Gabriela Coman

Success in the Emerging Asian Markets (EAMs) requires medical device companies to ensure superior product and patent protection for both their products and related methods of use, given the ease with which devices can be copied by competitors.

In China, India, Indonesia, Korea, Malaysia, the Philippines, Taiwan, Thailand, Mongolia, Pakistan, Sri Lanka and Vietnam – the countries that can be grouped together as the Emerging Asian Markets (EAMs) – securing patent protection is critical.

Once in possession of a patent, a medical device company will be able to create legal barriers to entry for competing devices by preventing others from copying, selling or manufacturing the patented device. It will also be able to license the patented device to generate revenues.

Furthermore, the value of the medical device company can be enhanced via the equity and asset building associated with the patent, which in turn may attract further investment.

  • EAM patents applicants need to be aware of current and future business development objectives, market specifics and how local competitors could design around the patented devices of the company.
  • Filing in multiple countries can be prohibitively expensive, but mechanisms to control fees and costs include international application/PCT applications, or concepts such as the newly launched ASEAN Patent Examination Cooperation program.
  • All EAM countries observe a "first- to-file" rule in granting patents, which, in cases where two different entities apply for a patent, it is the first one to file an application that will obtain the patent if the invention is patentable. The US adopted this law in 2013.
  • What is patentable and what is not can be something of a minefield, with different EAMs applying different criteria to patentable matter, so the regulations of each country require careful scrutiny.

FIVE FACTORS TO FORESTALL FAILURE

But early in the pathway leading to an EAM launch of a medical de- vice, there are five factors that a company needs to consider or act on, centering around:

Core Technology Assessments And Tailoring Patent Portfolios To Individual EAMs

Medical device companies interested in not-fully-developed patent markets, such as the EAMs, should develop a product patent portfolio that is tailored to the needs of each respective emerging market. The first stage for the medical device company is to assess the core technology and file patent applications that are designed to provide the broadest possible coverage of the core technology.

The company must consider: its current and future business development objectives; the ways that local competitors could design around its patented devices; the specific needs of the markets targeted – the Chinese vascular or ultrasound scan market or the Indian orthopedic market, say – and the way the patented technology could affect them; and whether to file national, regional or PCT (patent cooperation treaty) applications. Broad patent coverage, when and where applicable, should be directed to the entire medical device, it sub- components, methods of manufacturing, methods of use and treatment, therapeutic uses and any other aspects of the invention.

For example, for sophisticated medical de- vices like blood glucose monitoring systems, claims directed to user interface, software, power-management system and IC chips, among others, may also be filed separately to protect fully the scope of the claimed invention.

Patentable Matter May Be Different In The EAMs Compared With The US/ Europe Medical devices are protected and patent- able in EAM counties and the US. Methods of surgery and medical treatment methods may be protected and patentable in the US and Australia, but they are typically not protected in Europe or in EAM counties such as China, India or Thailand.

In most countries, methods that include a surgical step on a human or animal body are not patentable, even if the effect of surgery is not therapeutic. Claim terms such as "non- medical" or "diagnostic" could be used to make a claim acceptable (provided that the claim could be reasonably interpreted to be directed to a non-medical method without producing a therapeutic effect).

CHINA

In China, neither methods of medical treatment nor diagnostic methods are pat- entable subject matter. How- ever, devices and apparatus for implementing these methods of diagnosis or medical treatment, including substances and compositions for use in such methods, are patentable subject matter. For claims of treatment of diseases, these could be written in the form of pharmaceutical or use claims such as"method for preparing a pharmaceu- tical." Also, the scope of the claims must be commensurate with the working examples provided in the specification.

INDIA

Similarly, in India, methods of surgical treatment of the human or animal body (by surgery or therapy) or methods of diagnosis are not patentable subject matter.

Patents may be obtainable, however, for surgical, therapeutic or diagnostic instruments or apparatus. In addition, the manufacture of prostheses or artificial limbs, and taking measurements of the human body, may be patentable.

KOREA/THAILAND

In Korea, methods of treating humans are not patentable. However, methods of treating non-human animals are patentable, as are methods which are non-therapeutic, such as cosmetic applications. In Thailand, methods of medical treatment are not patentable subject matter.

In contrast, in the US, surgical techniques and methods of medical treatment, as well as methods of diagnosis or treatment, are patentable subject matter. For example, an instrument that cuts bone in a retrograde manner to form a bone tunnel or socket may be patentable in both the US and in the EAMs. A method of arthroscopic surgery to form a bone tunnel or socket using a retrograde cut- ter instrument may be patentable in the US but not in most EAM countries, where methods of medical treatment are unpatentable.

Patent Standards And Systems Are Different In EAM Countries

EAM countries apply various patent standards when assessing whether a medical device invention is patentable. These standards are different from those applied in the US, that is, novelty and non-obviousness. Under Chapter 35 of the USC (United States Code) in §§102, 103, it states that an invention must be novel and non-obvious to be patentable. The requirement of novelty means that the invention (medical device or method) must be new, that is, not previously known or used by others. The requirement of non- obviousness means that the invention must not be an obvious variation or combination of subject matter previously known to those of ordinary skill in the art.

In India, the patentability requirements for an invention are: novelty (the medical device must be new), non-obviousness (the medical device has to involve an inventive step), and industrial applicability (the medical device can be made or used in industry). Apart from satisfying these criteria, the invention should also not fall under the category of non-patentable subject matter of the Indian Patent Act. China adopts a dual approach in determining whether an invention could be considered inventive and thus patentable: "prominent substantive features" and" notable progress." Article 22 (3) of the Patent Law of the People's Republic of China prescribes that "inventiveness means that, as compared with the technology existing before the date of filing, the invention has prominent substantive features and represents notable progress, and that the utility model has substantive features and represents progress."

Under China's Guidelines on Examination of Patents," prominent substantive features" refer to "non-obviousness" and the examiner must conduct tests to establish the proximate prior art and the distinctive features of the invention and the technology issue to be solved, and must make a judgment on whether the invention seeking to be protected has obviousness to those skilled in the art.

"Notable progress" may be shown in the form of the "effect" of the invention or "the useful technological effective result." The Guidelines on Examination of Patents interpret the useful "effect" as: an invention that has a better effect than the prior art, an invention that has a technical solution involving a totally different concept but that has a similar effective result to the prior art, and an invention that represents a new trend of technological development.

In Korea, the criterion applied is whether it would be difficult for a person skilled in the art to arrive at the claimed invention.

All EAM countries observe a "first-to-file" rule in granting patents, a rule that was adopted in the US in 2013. Under "first to file," when two different entities apply for a patent, the first one to file an application will obtain the patent if the invention is patent- able. The US move to a "first-to-file" rule was a change from its prior "first-to-invent" rule.

US patent law adopted this major change to harmonize its patent process with that of the European Patent Office (EPO) and those of other foreign countries. In an effort to ease the transition from the" first-to-invent" to the "first-to-file" system, US patent law provides a one-year grace period, meaning that the inventor (or the person who directly obtained the information from the inventor) has the right to publish his/her invention within a year of filing the application without losing patent rights.

In contrast, no EAM countries observe a grace period. Most countries of the EAM group – and in Europe – apply an absolute novelty standard, meaning that any public disclosure of invention before the filing of a patent application will render the invention unpatentable. If the invention has become publicly available in any way prior to the filing of the application, the application will be rejected. "Publicly available" is typically defined as including: selling the invention; publishing the invention in a printed publication, such as a specialist brochure or magazine; giving a lecture about the invention; or presenting it to an investor without a non-disclosure agreement. The invention may be made "publicly available" by anyone, including the inventor(s) or any independent third party. Thus, if an inventor releases – before the filing of a patent application – a surgical brochure describing a medical device, the inventor will be barred from obtaining patent protection for the medical device in the EAM countries, whereas in the US, the inventor has one year from the release of the surgical brochure to file a patent application.

Best mode requirement is not a prerequisite to patentability in Taiwan and Korea. In Thailand and India, the patent specification must include the best method for performing the invention known to the applicant. In China, the specification must sufficiently describe details about the" preferred embodiments" or "optimized embodiments" but no oath from the applicant is required.

Opposition proceedings are not available in Taiwan (but relevant prior art may be submitted for consideration) and China (but patent invalidation may be available after grant of the patent). India, Thailand and Korea provide opposition proceedings. India, for example, allows for pre-grant opposition any time before publication and post-grant before expiration of a one-year period from the publication of the grant of the patent.

Filing Costs Are Different For National, Regional And PCT Applications

A patent is only enforceable in the jurisdiction in which it is granted. If a medical de- vice company seeks worldwide protection of a medical device, it must file a patent in each individual country worldwide. Filing in multiple countries, however, can be prohibitively expensive.

Various fees are associated with securing a patent. These fees include filing fees, fees for prosecuting the application, issue and maintenance fees, once the application has matured into a patent, and attorney fees, among others. Depending on the country or region, these fees may vary widely and may be spread unevenly over the course of filing and prosecuting an application, and maintenance of the patent.

One method of controlling these costs is the filing of an international application or a PCT application. The international application does not mature into a single international patent; however, it provides the company with the opportunity to delay making a final decision on whether to file a national application in member countries – for up to 30 months in most countries. During this period of time, the company applying for the patent can: assess whether the medical device is commercially viable, raise funds, explore potential markets and decide whether to enter the national/regional phase.

For the over 100 countries that are not members of the PCT (including Asian countries such as Cambodia and Myanmar), a patent application must be filed with the national patent office of the specific country to secure patent protection in that country. Direct national filing avoids the costs associated with the intermediate steps of filing via the PCT or a regional patent office prior to filing nationally.

ASEAN (the Association of Southeast Asian Nations) Patent Examination Cooperation (also known as ASPEC) has been recently launched as a regional patent cooperation program for sharing patent searches and examination results. ASPEC resembles a regional network of patent prosecution highways (PPHs) in the sense that each of the nine IP offices in the ASEAN countries accepts a patent application for expedited examination and search. In this manner, the results of search and examination from one country are used to expedite progress in the other countries.

Enforcement Of Patent Rights In EAM Countries May Be Limited

As noted, what may be patentable in the US may not be patentable in EAM countries and, even if patented, enforcement of the patented subject matter varies greatly. For example, methods of medical treatment are considered to fall outside the scope of patent protection in most countries including South Korea and European countries.

Although EAM countries have been gradually revising their patent laws to ren- der patents more valuable, medical device companies are not well-positioned when it comes to patent litigation and enforcing patent rights.

For example, while the courts in India (the District Court or a High Court) have gradually changed their understanding of complex patent infringement and validity issues, India still ranked as last in the Global Intellectual Property Center Index of 2014 (conducted by the US Chamber of Commerce), due mainly to its weak IP protection and enforcement.

Originally published by Informa Business Intelligence Inc.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions